IL135965A0 - Adenosine a1 receptor agonists - Google Patents
Adenosine a1 receptor agonistsInfo
- Publication number
- IL135965A0 IL135965A0 IL13596598A IL13596598A IL135965A0 IL 135965 A0 IL135965 A0 IL 135965A0 IL 13596598 A IL13596598 A IL 13596598A IL 13596598 A IL13596598 A IL 13596598A IL 135965 A0 IL135965 A0 IL 135965A0
- Authority
- IL
- Israel
- Prior art keywords
- adenosine
- receptor agonists
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9723566.7A GB9723566D0 (en) | 1997-11-08 | 1997-11-08 | Chemical compounds |
PCT/EP1998/007022 WO1999024450A2 (en) | 1997-11-08 | 1998-11-06 | Adensine a1 receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL135965A0 true IL135965A0 (en) | 2001-05-20 |
Family
ID=10821742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13596598A IL135965A0 (en) | 1997-11-08 | 1998-11-06 | Adenosine a1 receptor agonists |
Country Status (24)
Country | Link |
---|---|
US (1) | US6407076B1 (hu) |
EP (1) | EP1027363B1 (hu) |
JP (1) | JP2001522858A (hu) |
KR (1) | KR20010031883A (hu) |
CN (1) | CN1285842A (hu) |
AP (1) | AP2000001803A0 (hu) |
AT (1) | ATE242259T1 (hu) |
AU (1) | AU1232799A (hu) |
BR (1) | BR9813973A (hu) |
CA (1) | CA2309199A1 (hu) |
DE (1) | DE69815378T2 (hu) |
EA (1) | EA200000393A1 (hu) |
EE (1) | EE200000284A (hu) |
ES (1) | ES2201552T3 (hu) |
GB (1) | GB9723566D0 (hu) |
HR (1) | HRP20000276A2 (hu) |
HU (1) | HUP0004106A2 (hu) |
IL (1) | IL135965A0 (hu) |
IS (1) | IS5478A (hu) |
NO (1) | NO20002360L (hu) |
PL (1) | PL341091A1 (hu) |
SK (1) | SK6712000A3 (hu) |
TR (1) | TR200002157T2 (hu) |
WO (1) | WO1999024450A2 (hu) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214665B2 (en) | 2001-10-01 | 2007-05-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
US6576619B2 (en) * | 1999-05-24 | 2003-06-10 | Cv Therapeutics, Inc. | Orally active A1 adenosine receptor agonists |
US6784165B1 (en) | 1999-11-23 | 2004-08-31 | Aderis Pharmaceuticals, Inc. | Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines |
US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
AU4138601A (en) * | 1999-12-03 | 2001-06-12 | Cv Therapeutics, Inc. | Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias |
US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
GB9930077D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
CA2414623A1 (en) * | 2000-08-01 | 2002-02-07 | University Of Virginia Patent Foundation | Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis |
GB2372741A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,8-Disubstituted adenosine derivatives and their different uses |
GB2372742A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
GB0106867D0 (en) | 2001-03-20 | 2001-05-09 | Glaxo Group Ltd | Process |
US6995148B2 (en) * | 2001-04-05 | 2006-02-07 | University Of Pittsburgh | Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy |
US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
JP2006515829A (ja) * | 2002-04-10 | 2006-06-08 | ユニバーシティ オブ バージニア パテント ファウンデーション | 炎症性疾病の処置のための、a2aアデノシン受容体アゴニストの使用 |
EP1375508A1 (en) * | 2002-06-27 | 2004-01-02 | Aventis Pharma Deutschland GmbH | N6-substituted adenosine analogues and their use as pharmaceutical agents |
US7265111B2 (en) * | 2002-06-27 | 2007-09-04 | Sanofi-Aventis Deutschland Gmbh | Adenosine analogues and their use as pharmaceutical agents |
CA2515068A1 (en) | 2003-02-03 | 2004-08-19 | Cv Therapeutics Inc. | Partial and full agonists of a1 adenosine receptors |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
US20050277615A1 (en) * | 2004-05-17 | 2005-12-15 | Can-Fite Biopharma Ltd. | Pharmaceutical compositions having anti-inflammatory activity |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
WO2006028618A1 (en) * | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
EP1778712B1 (en) * | 2004-08-02 | 2013-01-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
US8178509B2 (en) * | 2006-02-10 | 2012-05-15 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
CA2664378A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as pi3k lipid kinase inhibitors |
CA2667962A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
AU2009203693B2 (en) | 2008-01-11 | 2012-06-07 | Novartis Ag | Pyrimidines as kinase inhibitors |
TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
CA2770873A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
IN2012DN01961A (hu) | 2009-08-17 | 2015-08-21 | Intellikine Llc | |
EP2467383A1 (en) | 2009-08-20 | 2012-06-27 | Novartis AG | Heterocyclic oxime compounds |
SG10201502588UA (en) | 2010-01-11 | 2015-05-28 | Inotek Pharmaceuticals Corp | Combination, kit and method of reducing intraocular pressure |
US9199914B2 (en) * | 2010-02-03 | 2015-12-01 | Meh Associates, Inc. | Multiple substituted fluoromethanes as selective and bioactive isosteres |
JP2013523739A (ja) | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン, エルエルシー | 複素環化合物およびその使用 |
SG192795A1 (en) | 2011-02-25 | 2013-09-30 | Irm Llc | Compounds and compositions as trk inhibitors |
ES2691650T3 (es) | 2011-09-15 | 2018-11-28 | Novartis Ag | 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met |
US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
SG11201403979TA (en) | 2012-01-26 | 2014-08-28 | Inotek Pharmaceuticals Corp | Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof |
RU2660354C2 (ru) | 2012-04-03 | 2018-07-05 | Новартис Аг | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
EP2968389A4 (en) | 2013-03-15 | 2016-08-24 | Inotek Pharmaceuticals Corp | OPHTHALMIC FORMULATIONS |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
CN107207510B (zh) | 2014-07-31 | 2019-11-29 | 诺华股份有限公司 | 联合疗法 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988003147A1 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
US5652366A (en) * | 1990-09-25 | 1997-07-29 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof |
US5561134A (en) | 1990-09-25 | 1996-10-01 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
WO1997033591A1 (en) * | 1996-03-13 | 1997-09-18 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
GB9610031D0 (en) * | 1996-05-14 | 1996-07-17 | Glaxo Group Ltd | Chemical compounds |
US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
-
1997
- 1997-11-08 GB GBGB9723566.7A patent/GB9723566D0/en not_active Ceased
-
1998
- 1998-11-06 HU HU0004106A patent/HUP0004106A2/hu unknown
- 1998-11-06 EP EP98955538A patent/EP1027363B1/en not_active Expired - Lifetime
- 1998-11-06 AT AT98955538T patent/ATE242259T1/de not_active IP Right Cessation
- 1998-11-06 IL IL13596598A patent/IL135965A0/xx unknown
- 1998-11-06 AU AU12327/99A patent/AU1232799A/en not_active Abandoned
- 1998-11-06 AP APAP/P/2000/001803A patent/AP2000001803A0/en unknown
- 1998-11-06 PL PL98341091A patent/PL341091A1/xx unknown
- 1998-11-06 DE DE69815378T patent/DE69815378T2/de not_active Expired - Fee Related
- 1998-11-06 EA EA200000393A patent/EA200000393A1/ru unknown
- 1998-11-06 KR KR1020007004974A patent/KR20010031883A/ko not_active Application Discontinuation
- 1998-11-06 BR BR9813973-8A patent/BR9813973A/pt not_active Application Discontinuation
- 1998-11-06 SK SK671-2000A patent/SK6712000A3/sk unknown
- 1998-11-06 ES ES98955538T patent/ES2201552T3/es not_active Expired - Lifetime
- 1998-11-06 US US09/530,574 patent/US6407076B1/en not_active Expired - Fee Related
- 1998-11-06 JP JP2000520458A patent/JP2001522858A/ja active Pending
- 1998-11-06 WO PCT/EP1998/007022 patent/WO1999024450A2/en not_active Application Discontinuation
- 1998-11-06 EE EEP200000284A patent/EE200000284A/xx unknown
- 1998-11-06 CN CN98812978A patent/CN1285842A/zh active Pending
- 1998-11-06 TR TR2000/02157T patent/TR200002157T2/xx unknown
- 1998-11-06 CA CA002309199A patent/CA2309199A1/en not_active Abandoned
-
2000
- 2000-05-03 IS IS5478A patent/IS5478A/is unknown
- 2000-05-05 NO NO20002360A patent/NO20002360L/no not_active Application Discontinuation
- 2000-05-08 HR HR20000276A patent/HRP20000276A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL341091A1 (en) | 2001-03-26 |
CN1285842A (zh) | 2001-02-28 |
US6407076B1 (en) | 2002-06-18 |
JP2001522858A (ja) | 2001-11-20 |
HRP20000276A2 (en) | 2000-12-31 |
TR200002157T2 (tr) | 2000-11-21 |
ES2201552T3 (es) | 2004-03-16 |
EA200000393A1 (ru) | 2000-12-25 |
AP2000001803A0 (en) | 2000-06-30 |
KR20010031883A (ko) | 2001-04-16 |
NO20002360D0 (no) | 2000-05-05 |
NO20002360L (no) | 2000-07-05 |
HUP0004106A2 (hu) | 2001-04-28 |
SK6712000A3 (en) | 2001-01-18 |
IS5478A (is) | 2000-05-03 |
DE69815378D1 (de) | 2003-07-10 |
DE69815378T2 (de) | 2004-04-29 |
AU1232799A (en) | 1999-05-31 |
GB9723566D0 (en) | 1998-01-07 |
BR9813973A (pt) | 2000-09-26 |
EE200000284A (et) | 2001-08-15 |
CA2309199A1 (en) | 1999-05-20 |
EP1027363A2 (en) | 2000-08-16 |
EP1027363B1 (en) | 2003-06-04 |
ATE242259T1 (de) | 2003-06-15 |
WO1999024450A3 (en) | 1999-08-19 |
WO1999024450A2 (en) | 1999-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL135966A0 (en) | Adenosine a1 receptor agonists | |
IL135965A0 (en) | Adenosine a1 receptor agonists | |
IL135964A0 (en) | Adenosine a1 receptor agonists | |
GB2353527B (en) | Adenosine A3 receptor modulators | |
IL147198A0 (en) | N-pyrazole a2a receptor agonists | |
IL147195A0 (en) | C-pyrazole a2a receptor agonists | |
AU5203999A (en) | Beta3-adrenergic receptor agonists | |
EP0979228A4 (en) | CANNABINOID RECEPTOR AGONISTS | |
EP1019427A4 (en) | N? 6 -SUBSTITUES-ADENOSINE-5'-URONAMIDES USEFUL AS MODULATORS OF ADENOSINE RECEPTORS | |
IL133920A0 (en) | Trail receptor | |
EP0929218A4 (en) | R2Y RECEPTOR ANTAGONISTS | |
IL146471A0 (en) | Orally active a1 adenosine receptor agonists | |
AU4980999A (en) | A3 adenosine receptor antagonists | |
EP1084142A4 (en) | GPR35A RECEIVER | |
EP0973800A4 (en) | NEW RECEIVER | |
EP1036064A4 (en) | SELECTIVE BETA 3-ADRENERGIC ANTAGONISTS | |
GB9819420D0 (en) | Novel receptor | |
EP1092017A4 (en) | GABA-B RECEIVER | |
EP1083909A4 (en) | hCEPR RECEPTOR | |
ZA987267B (en) | Nucleosides | |
IL156851A0 (en) | Adenosine a3 receptor modulators | |
IL156852A0 (en) | Adenosine a3 receptor modulators | |
EP1109565A4 (en) | GABAB1AA RECEPTOR | |
HU0002453D0 (en) | Novel nucleosides | |
GB9808613D0 (en) | Receptor system |